With the successful application of immune checkpoint inhibitors (ICIs), tyrosine kinase inhibitors (TKIs), and vascular endothelial growth factor (VEGF)‐targeted drugs, there is an increased demand for individualized and integrated treatments for RCC, especially for metastatic RCC.6 Here, VEGFA is linked to renal cell carcinoma.